Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

If You Invested $100 In GrowGeneration 5 Years Ago, Here's How Much You Would Have Today

GrowGeneration (NASDAQ:GRWG) has outperformed the market over the past 5 years by 6.84% on an annualized basis producing an average annual return of 17.46%. Currently, GrowGeneration has a market capitalization of $285.19 million.

Benzinga

Earnings Outlook For Celsion

Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-0.99.

Benzinga

Albireo Pharma's Earnings Outlook

Albireo Pharma (NASDAQ:ALBO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Albireo Pharma will report an earnings per share (EPS) of $-1.85.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC

Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells. NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.

Benzinga

Earnings Outlook For Take-Two Interactive

Take-Two Interactive (NASDAQ:TTWO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Take-Two Interactive will report an earnings per share (EPS) of $1.04.

Benzinga

Analyst Ratings for Outbrain

Over the past 3 months, 6 analysts have published their opinion on Outbrain (NASDAQ:OB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Brainstorm Cell Earnings Preview

Brainstorm Cell (NASDAQ:BCLI) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Brainstorm Cell will report an earnings per share (EPS) of $-0.13.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking At Microsoft's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Microsoft (NASDAQ:MSFT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Upgrades

Benzinga

Carrols Restaurant Group Earnings Perspective: Return On Capital Employed

Carrols Restaurant Group (NASDAQ:TAST) brought in sales totaling $399.48 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 29.69%, resulting in a loss of $21.27 million.

Benzinga

Masimo's Return on Invested Capital Insights

According to Benzinga Pro, during Q1, Masimo (NASDAQ:MASI) earned $46.59 million, a 31.74% increase from the preceding quarter. Masimo's sales decreased to $304.24 million, a 7.12% change since Q4.

Benzinga

MiMedx Group's Return on Invested Capital Insights

Benzinga Pro data, MiMedx Group (NASDAQ:MDXG) reported Q1 sales of $58.89 million. Earnings fell to a loss of $10.49 million, resulting in a 573.54% decrease from last quarter.

Benzinga

Looking Into DermTech's Return On Capital Employed

Benzinga Pro data, DermTech (NASDAQ:DMTK) reported Q1 sales of $3.72 million. Earnings fell to a loss of $30.11 million, resulting in a 15.56% decrease from last quarter.

Benzinga

Veracyte Earnings Perspective: Return On Capital Employed

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Viant Technology's Return On Capital Employed Overview

Benzinga Pro data, Viant Technology (NASDAQ:DSP) reported Q1 sales of $42.63 million. Earnings fell to a loss of $13.56 million, resulting in a 280.41% decrease from last quarter.

Benzinga

Looking Into TuSimple Hldgs's Return On Invested Capital

According to Benzinga Pro data, during Q1, TuSimple Hldgs (NASDAQ:TSP) posted sales of $2.26 million. Earnings were up 3.11%, but TuSimple Hldgs still reported an overall loss of $111.90 million.

Benzinga

Infinity Pharmaceuticals's Return On Capital Employed Insights

Benzinga Pro data, Infinity Pharmaceuticals (NASDAQ:INFI) reported Q1 sales of $652.00 thousand. Earnings fell to a loss of $12.44 million, resulting in a 6.74% decrease from last quarter.

Benzinga

Green Brick Partners's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Green Brick Partners (NASDAQ:GRBK) posted Q1 earnings of $64.20 million, an increase from Q4 of 4.3%. Sales dropped to $393.62 million, a 12.97% decrease between quarters.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Surgery Partners Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, Surgery Partners (NASDAQ:SGRY) posted Q1 earnings of $42.80 million, an increase from Q4 of 0.23%. Sales dropped to $596.20 million, a 2.29% decrease between quarters.

Benzinga

Daseke Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, Daseke (NASDAQ:DSKE) earned $13.00 million, a 83.1% increase from the preceding quarter. Daseke also posted a total of $421.00 million in sales, a 6.77% increase since Q4.

Benzinga

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Benzinga

Harmony Biosciences Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters.

Benzinga

Esperion Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but Esperion Therapeutics still reported an overall loss of $56.73 million.

Benzinga

Kymera Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter.

Benzinga

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million.

1 … 513 514 515 516

Organisations

United Parcel Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.